Abstract
Low Dose Intrathecal Morphine Monotherapy (LDITM) following systemic opioid weaning has been described to be effective in the management of chronic nonmalignant pain (NMP). However, multicenter evidence is limited. We report the results of the Embrace TDD study evaluating pain control and opioid side effects after a change from systemic opioids to LDITM in patients with NMP administered via an intrathecal (IT) delivery system.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Neuromodulation: Technology at the Neural Interface
Paper Title
Journal
Date
